Pfizer (XSWX:PFE) Accounts Payable: CHF3,548 Mil (As of Mar. 2026)


XSWX:PFE Pfizer Inc XSWX:PFE
69 GF Score
Price CHF19.58
GF Value CHF20.75
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Accounts Payable?

Pfizer XSWX:PFE 69 Accounts Payable is CHF3,548 Mil as of Mar. 2026. GuruFocus rates XSWX:PFE with a GF Score™ of 69/100 and a GF Value™ of CHF20.75 (Fairly Valued). The stock has 5 warning signs investors should review.

Pfizer's Accounts Payable for the quarter that ended in Mar. 2026 was CHF3,548 Mil.

Pfizer's quarterly Accounts Payable increased from Sep. 2025 (CHF4,000 Mil) to Dec. 2025 (CHF4,176 Mil) but then declined from Dec. 2025 (CHF4,176 Mil) to Mar. 2026 (CHF3,548 Mil).

Pfizer's annual Accounts Payable declined from Dec. 2023 (CHF5,803 Mil) to Dec. 2024 (CHF5,022 Mil) and declined from Dec. 2024 (CHF5,022 Mil) to Dec. 2025 (CHF4,176 Mil).

Pfizer Accounts Payable Historical Data

* Premium members only.

The historical data trend for Pfizer's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Accounts Payable Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,137.34 6,343.26 5,802.81 5,022.38 4,175.76

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,630.06 4,200.99 3,999.61 4,175.76 3,547.57
XSWX:PFE
69GF Score
Pfizer Inc XSWX:PFE
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of CHF3,548 Mil mean?
Pfizer (XSWX:PFE) has a Accounts Payable of CHF3,548 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Pfizer and its competitors.
Is Pfizer's Accounts Payable too high?
Pfizer's current Accounts Payable is CHF3,548 Mil. Overall, Pfizer has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Accounts Payable compare to GILD and BMY?
Pfizer's Accounts Payable of CHF3,548 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Pfizer and its competitors. Pfizer's current Accounts Payable is CHF3,548 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF20.75, compared to a current price of CHF19.58 — trading 5.6% below its estimated fair value. The current Accounts Payable is CHF3,548 Mil. Pfizer's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Accounts Payable is CHF3,548 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (XSWX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of CHF19.58 is trading 5.6% below its estimated GF Value™ of CHF20.75. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for XSWX:PFE:

  • Accounts Payable: CHF3,548 Mil
  • GF Value™: CHF20.75 vs. price of CHF19.58 (5.6% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
69GF Score

Get the complete analysis for XSWX:PFE

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF19.58
Price
CHF20.75
GF Value